A novel monoacylglycerol lipase inhibitor with analgesic and anti-inflammatory activity

Victoria Magrioti[a,b], **George Naxakis**[a], **Dimitra Hadjipavlou-Litina**[c], **Alexandros Makriyannis**[b], and **George Kokotos**[a,*]

[a]Laboratory of Organic Chemistry, Department of Chemistry, University of Athens, Panepistimiopolis, Athens 15771, Greece

[b]Center for Drug Discovery, Northeastern University, 116 Mugar Hall, Boston, MA 02115, USA

[c]Department of Pharmaceutical Chemistry, University of Thessaloniki, 540 06 Thessaloniki, Greece

Abstract

A variety of long chain 1,2-diamines and related compounds were synthesized and tested for their activity on fatty acid amide hydrolase (FAAH) and monoacyglycerol lipase (MGL). (2S,9Z)-Octadec-9-ene-1,2-diamine selectively inhibits MGL (K_i 21.8 μM) without significantly affecting FAAH. This compound exhibited interesting in vivo analgesic and anti-inflammatory properties, suggesting that selective inhibitors of MGL may be valuable novel agents for the treatment of inflammatory pain.

Keywords

1,2-Diamines; Endocannabinoids; Fatty acid amide hydrolase; FAAH; Inhibitor; Monoacyglycerol lipase; MGL

The discovery of the CB1 and CB2 cannabinoid receptors as well as the endogenous ligand involved in their activation opened a new era in cannabinoid research.[1,2] The key endogenous ligands designated as endocannabinoids are anandamide (**1**) and 2-arachidonoylglycerol (2-AG, **2**) (Fig. 1). Of these, 2-AG has been shown to be the most abundant and more potent endocannabinoid.[3] 2-AG exhibits full agonist efficacy at both CB1 and CB2[4] and its physiological levels in rat brain exceed those of anandamide by several orders of magnitude.[3b] Although the endocannabinoid system has received much attention in recent years as a target for the discovery of novel therapeutic agents,[5] the role and function of 2-AG are less understood.

Anandamide and 2-AG are produced by neurons when the need arises, act near their site of biosynthesis, and are rapidly metabolized so that their biological activity is terminated. Both anandamide and 2-AG are hydrolyzed by fatty acid amide hydrolase (FAAH).[6] However, existing evidence indicates that the most likely candidate for 2-AG hydrolytic deactivation is monoacylglycerol lipase (MGL), a serine hydrolase that converts 1- and 2-monoacylglycerols into fatty acid and glycerol.[7] Dinh et al. cloned MGL from a rat brain cDNA,[8] and demonstrated that RNA interference suggested a primary role for MGL in the degradation of 2-AG.[9] More recently, Makriyannis and collaborators have characterized the

binding domain of this enzyme using a proteomic approach.[10] Although a plethora of FAAH inhibitors have been developed,[1,2,11] only few MGL inhibiting ligands are available.

Various nonspecific serine hydrolase inhibitors such as methylarachidonoyl fluorophosphonate (**3**, MAFP) (Fig. 2), hexadecylsulfonyl fluoride (AM374) and phenylmethylsulfonyl fluoride (PMSF) inhibit purified MGL, or 2-AG-degrading enzymatic activity in rat cerebellar membranes.[6d,8,12] In addition, sulfhydryl-specific compounds, like *N*-arachidonylmaleimide (**4**, NAM) have been shown to inhibit MGL.[13] Arachidonoyl trifluoromethyl ketone (**5**, ATFMK)[12] as well as arachidonoyl glycerol derivatives such as compound **6** also interact with MGL.[14] It has been reported that MGL activity can be specifically and noncompetitively inhibited by two compounds, URB602 (**7**) and URB754 (**8**) (Fig. 2).[15] However, a recent report showed that both URB602 and URB754 had no effect on the hydrolysis or signaling capacity of 2-AG in rat brain.[16] Most recently, it has been reported that locally injected 2-AG decreased pain behavior in a dose-dependent manner in an inflammatory model of pain.[17] It is thought that the antinociceptive effect of 2-AG is mediated through the CB2 receptor.

The novel finding that the exogeneous application of 2-AG induces peripheral antinociception,[17] reveals the therapeutic potential of MGL inhibitors for the treatment of inflammatory pain.[18] Since both FAAH and MGL may hydrolyse 2-AG, it is of great importance to develop selective inhibitors of these enzymes in order to fully explore the physiological role for 2-AG. Here, we describe our efforts towards the synthesis of MGL selective inhibitors and the in vivo anti-inflammatory and analgesic properties of such a compound.

During the last years we have developed a variety of inhibitors of lipolytic enzymes (pancreatic and gastric lipases as well as phospholipases cPLA$_2$ and iPLA$_2$),[19–25] and we have shown that the cytosolic phospholipase A$_2$ inhibitor AX048 produces a potent anti-hyperalgesic action.[26] All of these lipolytic enzymes are serine hydrolases with a mechanism of action involving a serine residue at the catalytic site interacting with a 2-oxoamide functionality of the inhibitors. Since MGL is also a serine hydrolase, we have incorporated the 2-oxoamide functionality in our MGL inhibitor design. Towards this end, we synthesized a lipid analog carrying the 2-oxoamide of ethanolamine. 2-Oxoamide **12** was prepared from the *tert*-butyl ether of ethanolamine as described in Scheme 1. This compound exhibited weak inhibitory activity towards both FAAH and MGL, with no selectivity (Table 1).

At the same time, we synthesized a series of long chain 1,2-diamines and 1,2-amino alcohols containing a saturated chain or a chain corresponding to that of oleic acid chain. (*S*)- and (*R*)-2-aminohexadecanol[27] (**13, 14**) and 1,2-diaminohexadecane[28] (**15**) were prepared as previously described. The synthesis of 1,2-diamine **21** is presented in Scheme 2. L-Glutamic acid was used as starting material and aminoaldehyde **16** was prepared according to literature procedure.[29] After a Horner–Wadsworth–Emmons reaction, hydrogenation with simultaneous reduction of the azide group and Boc protection, the key intermediate ester **18** was obtained. Compound **18** was then reduced to aldehyde **19**, which was allowed to react with the appropriate ylide to yield diamine **20**. Deprotection gave diamine **21**[30] which encompasses an oleic acid chain. Its enantiomer **22** was prepared correspondingly from D-glutamic acid.

Diamines **25a** and **25b** were prepared from aminoaldehyde **16** through a Wittig reaction followed by hydrogenation and simultaneous transformation of the azide group into a Boc-protected amine, and deprotection (Scheme 3).

Previously, we used Boc-protected (S)-2-amino oleic[31] acid to prepare a potent inhibitor of human pancreatic lipase, which resembled the natural substrate of the enzyme.[32] We now used this optically pure unnatural 2-amino acid (**26**) to prepare the carboxamide of 2-amino oleic acid (**29**) (Scheme 4).

All new compounds were tested for their abilities to inhibit 2-AG hydrolysis by FAAH and MGL (Table 1). Partially purified FAAH and MGL enzyme preparations were obtained from adult Sprague–Dawley rat brains purchased from Pel-Freeze Biologicals according to previously reported procedures,[33,34] while the FAAH and MGL inhibition assays were performed as previously described.[34–36]

2-Oxoamide **12** presented low inhibition and no selectivity towards the two enzymes. (S)- or (R)-2-aminohexadecanol (**13, 14**) as well as 1,2-diaminohexadecane (**15**) inhibit both enzymes equally. However, the unsaturated diamine, (2S,9Z)-octadec-9-ene-1,2-diamine dihydrochloride (**21**), inhibited MGL selectively with a K_i value of 21.8 μM. This compound did not inhibit FAAH significantly. Compound **21** also exhibited modest stereoselectivity. Its enantiomer (2R,9Z)-octadec-9-ene-1,2-diamine dihydrochloride (**22**), inhibits MGL with a K_i value of 39 μM, and some FAAH inhibitory activity (25% at a 100 μM).

Diamine **25a** was totally inactive towards both enzymes, while **25b**, which carries a para alkoxy chain, was weakly active. Thus, it appears that diamines require the presence of a long lipophilic chain in order to successfully inhibit MGL. Our results also indicate that the presence of a long monounsaturated chain corresponding to oleic acid in compound **21** is a key requirement for the selective inhibition of MGL. Recently, an oleoyl-chain phosphonate, UP-101, was reported to be a potent inhibitor of MGL.[37] Furthermore, according to a recent article, NAM exhibits approximately a 30-fold higher MGL inhibitory activity than compound **21**.[10] Conversely, the carboxamide of 2-amino oleic (**29**) acid does not inhibit MGL, but weakly inhibits FAAH. Thus, it appears that replacement of the CH_2NH_2 moiety of compound **21** by the $CONH_2$ led to a compound without inhibition towards MGL.

Subsequently, compound **21** was tested for its analgesic and anti-inflammatory activity using models previously described.[24] The acetic acid writhing test was used to assess analgesic activity in rats. Acetylsalicylate was used as a reference drug and was administered ip. As shown in Figure 3, **21** exhibited analgesic activity at a dose of 3.6 mg/kg (ip). A more potent effect was observed at a 10-fold higher dose indicating a dose-dependent effect. Furthermore, its enantiomer **22** exhibited similar analgesic activity at the high dose of 36 mg/kg, but had weaker analgesic potency at the lower dose of 3.6 mg/kg.

The rat paw carrageenan-induced edema assay was employed as a model for acute inflammation. Compound **21** exhibited in vivo anti-inflammatory activity (ED_{50} 0.01 mmol/kg) comparable to that of the reference drug indomethacin (47% inhibition of inflammation at 0.01 mmol/kg administered ip).

In conclusion, we synthesized a variety of long chain 1,2-diamines and related compounds and studied their effects on the endocannabinoid deactivating enzymes FAAH and MGL. We demonstrated that (2S,9Z)-octadec-9-ene-1,2-diamine is a novel selective inhibitor of MGL activity (K_i 21.8 μM) with in vivo analgesic and anti-inflammatory properties. Thus, synthetic selective inhibitors of MGL are potential candidates for the development of novel analgesic agents.

Acknowledgments

References and notes

1. Kokotos, G. Endocannabinoids. In: Kokotos, G.; Nicolaou, A., editors. Bioactive Lipids. The Oily Press; Bridgewater, England: 2004. p. 245

2. Lambert DM, Fowler CJ. J. Med. Chem. 2005; 48:5059. [PubMed: 16078824]

3. (a) Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminsky NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z. Biochem. Pharmacol. 1995; 50:83. [PubMed: 7605349] (b) Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K. Biochem. Biophys. Res. Commun. 1995; 215:89. [PubMed: 7575630] (c) Stella N, Schweitzer P, Piomelli D. Nature. 1997; 388:773. [PubMed: 9285589]

4. (a) Sugiura T, Kodaka T, Nakane S, Miyashita T, Kondo S, Suhara Y, Takayama H, Waku K, Seki C, Baba N, Ishima Y. J. Biol. Chem. 1999; 274:2794. [PubMed: 9915812] (b) Gonsiorek W, Lunn C, Fan X, Narula S, Lyndell D, Hipkin RW. Mol. Pharmacol. 2000; 57:1045. [PubMed: 10779390]

5. (a) Piomelli D. Curr. Opin. Investig. Drugs. 2005; 6:672.(b) Di Marzo V, Bifulco M, De Petrocallis L. Nat. Rev. Drug Disc. 2004; 3:771.(c) Makriyannis A, Mechoulam R, Piomelli D. 2005. Neuropharmacology. 48:1068. [PubMed: 15885714] (d) Bahr BA, Karanian DA, Makanji SS, Makriyannis A. Expert Opin. Investig. Drugs. 2006; 15:351.

6. (a) Desarnaud F, Cadas H, Piomelli D. J. Biol. Chem. 1995; 270:6030. [PubMed: 7890734] (b) Ueda N, Kurahashi Y, Yamamoto S, Tokunaga T. J. Biol. Chem. 1995; 270:23823. [PubMed: 7559559] (c) Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Nature. 1996; 384:83. [PubMed: 8900284] (d) Goparaju SK, Ueda N, Yamaguchi H, Yamamoto S. FEBS Lett. 1998; 422:69. [PubMed: 9475172] (e) Lang W, Qin C, Lin S, Khanolkar AD, Goutopoulos A, Fan P, Abouzid K, Meng Z, Biegel D, Makriyannis A. J. Med. Chem. 1999; 42:896. [PubMed: 10072686]

7. (a) Tornquist H, Belfrage P. J. Biol. Chem. 1976; 251:813. [PubMed: 1249056] (b) Karlsson M, Contreras JA, Hellman U, Tornqvist H, Holm C. J. Biol. Chem. 1997; 272:27218. [PubMed: 9341166]

8. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D. Proc. Natl. Acad. Sci. U.S.A. 2002; 99:10819. [PubMed: 12136125]

9. Dinh TP, Kathuria S, Piomelli D. Mol. Pharmacol. 2004; 66:1260. [PubMed: 15272052]

10. Zvonok N, Pandarinathan L, Williams J, Johnston M, Karageorgos I, Janero DR, Krishnan SC, Makriyannis A. Chem. Biol. 2008; 15:854. [PubMed: 18721756]

11. For selected references, see: Leung D, Du W, Hardouin C, Cheng H, Hwang I, Cravatt BF, Boger DL. Bioorg. Med. Chem. Lett. 2005; 15:1423. [PubMed: 15713400] ; Boger DL, Miyauchi H, Du W, Hardouin C, Fecik RA, Cheng H, Hwang I, Hedrick MP, Leung D, Acevedo O, Guimarães CRW, Jorgensen WL, Cravatt BF. J. Med. Chem. 2005; 48:1849. [PubMed: 15771430] ; Romero FA, Du W, Hwang I, Rayl TJ, Kimball FS, Leung D, Hoover HS, Apodaca RL, Breitenbucher JG, Cravatt BF, Boger DL. J. Med. Chem. 2007; 50:1058. [PubMed: 17279740] ; Hardouin C, Kelso MJ, Romero FA, Rayl TJ, Leung D, Hwang I, Cravatt BF, Boger DL. J. Med. Chem. 2007; 50:3359. [PubMed: 17559203] .

12. Saario SM, Savinainen JR, Laitinen JT, Jarvinen T, Niemi R. Biochem. Pharmacol. 2004; 67:1381. [PubMed: 15013854]

13. Saario SM, Salo OMH, Nevalainen T, Poso A, Laitinen JT, Jarvinen T, Niemi R. Chem. Biol. 2005; 12:649. [PubMed: 15975510]

14. Ghafouri N, Tiger G, Razdan RK, Mahadevan A, Pertwee RG, Martin BR, Fowler CJ. Br. J. Pharmacol. 2004; 143:774. [PubMed: 15492019]

15. Makara JK, Mor M, Fegley D, Szabo SI, Kathuria S, Astarita G, Duranti A, Tontini A, Tarzia G, Rivara S, Freund TF, Piomelli D. Nat. Neurosci. 2005; 8:1139. [PubMed: 16116451]

16. (a) Saario SM, Palomaki V, Lehtonen M, Nevalainen T, Jarvinen T, Laitinen JT. Chem. Biol. 2006; 13:811. [PubMed: 16931330] (b) Vandevoorde S, Jonsson K-O, Labar G, Persson E, Lambert DM, Fowler CJ. Br. J. Pharmacol. 2007; 150:186. [PubMed: 17143303]

17. Guindon J, Desroches J, Beaulieu P. Br. J. Pharmacol. 2007; 150:693. [PubMed: 17179944]

18. Hohmann AG. Br. J. Pharmacol. 2007; 150:673. [PubMed: 17293886]

19. Kokotos G, Verger R, Chiou A. Chem. Eur. J. 2000; 6:4211. [PubMed: 11128286]

20. Kotsovolou S, Chiou A, Verger R, Kokotos G. J. Org. Chem. 2001; 66:962. [PubMed: 11430119]

21. Chiou A, Verger R, Kokotos G. Lipids. 2001; 36:535. [PubMed: 11432468]

22. Kokotos G, Kotsovolou S, Verger R. ChemBioChem. 2003; 4:101. [PubMed: 12512083]

23. Kokotos G, Kotsovolou S, Six DA, Constantinou-Kokotou V, Beltzner CC, Dennis EA. J. Med. Chem. 2002; 45:2891. [PubMed: 12086476]

24. Kokotos G, Six DA, Loukas V, Smith T, Constantinou-Kokotou V, Hadjipavlou-Litina D, Kotsovolou S, Chiou A, Beltzner CC, Dennis EA. J. Med. Chem. 2004; 47:3615. [PubMed: 15214789]

25. Stephens D, Barbayianni E, Constantinou-Kokotou V, Peristeraki A, Six DA, Cooper J, Harkewicz R, Deems RA, Dennis EA, Kokotos G. J. Med. Chem. 2006; 49:2821. [PubMed: 16640343]

26. Yaksh TL, Kokotos G, Svensson CI, Stephens D, Kokotos CG, Fitzsimmons B, Hadjipavlou-Litina D, Hua X-Y, Dennis EA. J. Pharmacol. Exp. Ther. 2006; 316:466. [PubMed: 16203828]

27. Magrioti V, Hadjipavlou-Litina D, Constantinou-Kokotou V. Bioorg. Med. Chem. Lett. 2003; 13:375. [PubMed: 12565932]

28. Kokotos G, Constantinou-Kokotou V, del Olmo Fernandez E, Toth I, Gibbons WA. Liebigs Ann. Chem. 1992; 961

29. Markidis T, Kokotos G. J. Org. Chem. 2001; 66:1919. [PubMed: 11262148]

30. All new compounds were fully characterized by ^{1}H and ^{13}C NMR, MS and elemental analysis. Selected data of final inhibitor: Compound **21**: Waxy solid; $[a]_D^{25}$ −8.3(c = 0.7, CH$_3$OH); ^{1}H NMR (200MHz, CD$_3$OD) δ 0.90 (t, J = 5.2Hz, 3H, CH$_3$), 1.29 (br s, 8H, 4× CH$_2$), 1.39 (br s, 12H, 6× CH$_2$), 1.72 (m, 2H, CH_2CH), 2.04 (m, 4H, CH_2CH = CHCH_2), 3.32-3.23 (m, 2H, CH_2NH$_2$), 3.52 (m, 1H, CH), 5.35 (m, 2H, CH=CH); ^{13}C NMR (50MHz, CD$_3$OD): δ 14.5, 23.7, 26.0, 28.1, 30.1, 30.3, 30.4, 30.4, 30.6, 30.8, 30.9, 31.7, 39.1, 42.2, 50.9, 130.6, 131.0; MS (ESI) m/z (%) 283.2 (MH$^+$, 100).

31. (a) Constantinou-Kokotou V, Magrioti V, Markidis T, Kokotos G. J. Pept. Res. 2001; 58:325. [PubMed: 11606217] (b) Magrioti V, Constantinou-Kokotou V. Lipids. 2002; 37:223. [PubMed: 11908915]

32. Magrioti V, Verger R, Constantinou-Kokotou V. J. Med. Chem. 2004; 47:288. [PubMed: 14711301]

33. Lang W, Qin C, Hill WAG, Lin S, Khanolkar AD, Makriyannis A. Anal. Biochem. 1996; 238:40. [PubMed: 8660583]

34. Lang W, Qin C, Lin S, Khanolkar AD, Goutopoulos A, Fan P, Abouzid K, Meng Z, Biegel D, Makriyannis A. J. Med. Chem. 1999; 42:896. [PubMed: 10072686]

35. Qin C, Lin S, Lang W, Goutopoulos A, Pavlopoulos S, Mauri F, Makriyannis A. Anal. Biochem. 1998; 261:8. [PubMed: 9683506]

36. Vadivel SK, Vardarajan S, Duclos RI Jr. Wood JT, Guo J, Makriyannis A. Bioorg. Med. Chem. Lett. 2007; 17:5959. [PubMed: 17826996]

37. Bisogno T, Cascio MG, Saha B, Mahadevan A, Urbani P, Minassi A, Appendino G, Saturino C, Martin B, Razdan R, Di Marzo V. Biochim. Biophys. Acta. 2006; 1761:205. [PubMed: 16466961]

Anandamide
1

2-Arachidonoylglycerol (2-AG)
2

Figure 1.
The most important endocannabinoids.

**3**, MAFP

4, NAM

5, ATFMK

6

7, URB602

8, URB754

Figure 2.
Inhibitors of monoacylglycerol lipase.

Figure 3.
In vivo analgesic activity of inhibitors **21** and **22**. Control (■), 22 (3.6 mg/kg, ◆), **21** (3.6 mg/kg, ▲), **22** (36 mg/kg, ●), **21** (36 mg/kg, ×), aspirin (200 mg/kg, +).

Scheme 1.
Synthesis of 2-oxoamide **12**. Reagents: (a) $CH_3(CH_2)_{13}CHOHCOOH$, *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride, HOBt, Et_3N, CH_2Cl_2; (b) AcNH-TEMPO, NaOCl, NaBr, EtOAc=PhCH$_3$=H$_2$O; (c) 50% TFA=CH$_2$Cl$_2$.

Scheme 2.
Synthesis of 1,2-diamines **21** and **22**. Reagents: (a) EtOOCCH=CHCH$_2$P(=O)(OEt)$_2$, LiOH, THF; (b) H$_2$, 10% Pd/C, Boc$_2$O, MeOH; (c) DIBALH, Et$_2$O; (d) C$_9$H$_{19}$P$^+$Ph$_3$Br$^-$, KHMDS, toluene; (e) 4 N HCl/Et$_2$O.

Scheme 3.
Synthesis of diamines **25a** and **25b**. Reagents: (a) $R^1P^+Ph_3Br^-$, KHMDS, toluene; (b) H_2, 10% Pd/C, Boc_2O, MeOH; (c) 4 N HCl=Et_2O.

Scheme 4.
Synthesis of carboxamide **29**. Reagents: (a) Boc_2O, Et_3N, MeOH; (b) DCC, HOBt, 25% aq:NH_3, CH_2Cl_2, DMF; (c) 4N HCl/Et_2O.

Table 1

Inhibitory results on FAAH and MGL[a]

Structure	FAAH inhibition (%)	MGL inhibition (%)	K_i for MGL (μM)
12	23.8	27.5	
13	33.6	31.5	
14	31.3	30.0	
15	31.2	30.3	58.7
21	4.9	49.9	21.8
22	25.9	42.2	39.0
25a	0.0	0.0	
25b	30.9	25.9	
29	24.0	0.0	

[a] Percent inhibition of 2-AG hydrolysis using 100 μM concentrations.